Areteia Therapeutics
Bernardsville
About Areteia Therapeutics
Areteia Therapeutics is a biotechnology company committed to putting asthma patients in better control of their disease. The company was spun out of Pennsylvania-based Knopp, which published results from its phase 2 clinical trial last year that showed its oral drug candidate could reduce the count of blood eosinophil, which is an indication of improving lung function and is found in several asthma-related treatments.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $425.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Feb 2024)
- Website: areteiatx.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Life Science, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/areteia-therapeutics-45251 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.